Subscribe To
ORMP / Why Oramed Pharmaceuticals Stock Is On Fire Today
ORMP News
By The Motley Fool
January 12, 2023
Why Oramed Pharmaceuticals Stock Is Crashing Today
The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes. more_horizontal
By InvestorPlace
January 12, 2023
Why Is Oramed (ORMP) Stock Down 75% Today?
Oramed (NASDAQ: ORMP ) stock is falling hard on Thursday after releasing data from a Phase 3 clinical trial. This clinical trial saw Oramed testing th more_horizontal
By Market Watch
January 12, 2023
Oramed's oral insulin pill fails; stock is down 72%
Shares of Oramed Pharmaceuticals Inc. ORMP, +5.78% plunged 72% in premarket trading on Thursday, the day after the company told investors its oral ins more_horizontal
By Seeking Alpha
December 7, 2022
Oramed: NASH Biotech Play With Added Bonus
Oramed achieved positive results from phase 2 study using ORMD-0801 for Type 2 Diabetes patients with NASH. Primary safety endpoint and secondary expl more_horizontal
By The Motley Fool
July 12, 2022
Why Oramed Pharmaceuticals Stock Is On Fire Today
The biotech's stock has been ripping higher of late. more_horizontal
By Seeking Alpha
April 14, 2022
Oramed And Oral Insulin: Can This Small Company Really Do It?
Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity. more_horizontal